Table 1.
Baseline characteristics
| Total N = 185 | ATDW group n = 59 | ATC group n = 126 | P-value | |
|---|---|---|---|---|
| Age (median, IQR) | 68 (60.1–78.6) | 72 (60.1–82.1) | 67 (58.8–76.7) | .28 |
| Gender Male Female |
98 (53.0) 87 (47.0) |
27 (45.8) 32 (54.2) |
71 (56.4) 55 (43.7) |
.18 |
| Ethnicity Caucasian Black or African American Asian Hispanic Other |
109 (58.9) 24 (13.0) 13 (7.0) 19 (10.3) 18 (9.7) |
33 (55.9) 8 (13.6) 6 (10.2) 4 (6.8) 8 (13.6) |
76 (60.3) 16 (12.7) 13 (10.3) 9 (7.1) 10 (7.9) |
.57 .87 .98 1.00 .23 |
| Past Medical History Past or current smoker Malignancy COPD Asthma CKD Home oxygen Interstitial or chronic lung disease ESRD Chronic trach Pulmonary fibrosis |
65 (35.1) 58 (31.4) 42 (22.7) 21 (11.4) 26 (14.1) 32 (17.3) 15 (8.1) 12 (6.5) 2 (1.1) 2 (1.1) |
20 (33.9) 16 (27.1) 15 (25.4) 10 (17.0) 9 (15.3) 6 (10.2) 5 (8.5) 4 (6.8) 1 (1.7) 1 (1.7) |
45 (35.7) 42 (33.3) 27 (21.4) 11 (8.7) 17 (13.5) 26 (20.6) 10 (7.9) 8 (6.4) 1 (.8) 1 (.8) |
.81 .40 .55 .10 .75 .08 1.00 1.00 .54 .54 |
| Charlson Comorbidity Index | 8 (5–10) | 7 (5–10) | 8 (5–10) | .25 |
| Immunocompromised | 50 (27.0) | 13 (22.0) | 37 (29.4) | .30 |
| Type (N, %) Immunosuppressive medications Chemo/radiation/immunotherapy<3 month Prednisone ≥20 mg/d Immunocompromising condition ANC<500 (cells/uL) |
19 (38.0) 22 (44.0) 5 (10.0) 5 (10.0) 3 (6.0) |
N = 13 7 (53.9) 6 (46.2) 1 (7.7) 0 0 |
N = 37 12 (32.4) 16 (43.2) 4 (10.8) 5 (13.5) 3 (8.1) |
|
| Antibiotic allergies Penicillin Cephalosporin Sulfa antibiotic Fluoroquinolone Tetracycline Aminoglycoside Macrolide Carbapenem Vancomycin Clindamycin NKA |
29 (15.7) 5 (2.7) 10 (5.4) 5 (2.7) 2 (1.1) 2 (1.1) 2 (1.1) 1 (.5) 1 (.5) 1 (.5) 144 (77.8) |
8 (13.6) 2 (3.4) 2 (3.4) 2 (3.4) 2 (3.4) 2 (3.4) 1 (1.7) 0 0 0 46 (78.0) |
21 (16.7) 3 (2.4) 8 (6.4) 3 (2.4) 0 0 1 (.8) 1 (.8) 1 (.8) 1 (.8) 98 (77.8) |
.59 .66 .51 .66 .10 .10 1.00 1.00 1.00 1.00 .98 |
| CXR reading Interstitial opacities Consolidation Infiltrates Pulmonary cavitation Other |
146 (78.9) 34 (18.4) 16 (8.7) 3 (1.6) 24 (13.0) |
47 (79.7) 9 (15.3) 5 (8.5) 0 11 (18.6) |
99 (78.6) 25 (19.8) 11 (8.7) 3 (2.4) 13 (10.3) |
.87 .45 .95 .55 .12 |
| Hospital length of stay (median, IQR) | 8.0 (5.0–14.2) | 8.3 (4.4–14.1) | 7.8 (5.1–15.7) | .96 |
| Pneumonia type CAP HAP VAP |
134 (72.4) 44 (23.8) 7 (3.8) |
35 (59.3) 22 (37.329) 2 (3.4) |
99 (78.6) 22 (17.5) 5 (4.0) |
.006 .003 1.00 |
| Viral PNA | 15 (8.1) | 6 (10.2) | 9 (7.1) | .57 |
| Covid PNA | 24 (13.0) | 11 (18.6) | 13 (10.3) | .12 |
| Prior hospitalization<90 d | 72 (38.9) | 21 (35.6) | 51 (40.5) | .53 |
| Highest WBC within 48 h | 11.7 (7.4–16.5) | 10.0 (7.4–13.3) | 13.2 (7.4–18.1) | .04 |
| qPitt Bacteremia Score | 1 (0–2) | 1 (0–1) | 1 (0–3) | .02 |
| ICU admission and/or intubation | 93 (50.3) | 24 (40.7) | 69 (54.8) | .10 |
| ICU admission | 90 (48.7) | 24 (40.7) | 66 (52.4) | .14 |
| ICU Type MICU NICU SICU CCU |
61 (33.0) 9 (4.9) 11 (6.0) 8 (4.3) |
N = 24 11 (18.6) 6 (10.2) 4 (6.8) 2 (3.4) |
N = 66 50 (39.7) 3 (2.4) 7 (5.6) 6 (4.8) |
|
| ICU length of stay, median (IQR) | 5.8 (2.9–12.9) | 4.4 (1.1–9.9) | 6.9 (3.3–13.4) | .05 |
| Intubation | 63 (34.1) | 17 (28.8) | 46 (36.5) | .34 |
| Duration of intubation, median (IQR) | 5.0 (2.0–10.9) | 4.5 (1.4–13.2) | 5.0 (2.0–10.4) | .97 |
All data are represented as n (%) unless specified otherwise.